Business intelligence reports for the lab diagnostics industry

Subscribe for Exclusive Access.

Subscriptions & Reports

Diagnostic Testing & Emerging Technologies

Stay up to date on new diagnostic tests, trends and opportunities, and emerging technologies

Learn More

Lab Compliance Advisor

Everything you need to know to comply with the latest laws, rules, and regulations

Learn More

Laboratory Industry Report

The latest in diagnostic lab business and competitive strategy, trends, and M&A and investment activity

Learn More

National Lab Reporter

The latest on laws, regulations, and new legislation that affect your diagnostic lab or pathology practice

Learn More

Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.

No Results Found

The posts you requested could not be found. Try changing your module settings or create some new posts.

No Results Found

The posts you requested could not be found. Try changing your module settings or create some new posts.

No Results Found

The posts you requested could not be found. Try changing your module settings or create some new posts.

CLIA-lcaCLIA-nirCompliance-lcaEssentialFDA-lcaFDA-lirFDA-nirLab Industry AdvisorLabs in Court-lcaLabs in Court-nirLDTs-lirOscelle Boye, MBiomed

Next Steps: With LDT Final Rule Now Null, Industry Groups Urge Lab Managers and Pathologists to Advocate for Change

CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight

Subscribe to View

Start a Free Trial for immediate access to this article

Try For Free

Already a member? Log in here
With a judge having vacated the LDT final rule, CAP and AMP officials promote future advocacy as a next step.